The “Ozempic Economy”: What Happens When People Change Faster Than Businesses

It started as a medical story.

Drugs like Ozempic and Wegovy were developed to treat diabetes and obesity, but now they are reshaping something much broader: how people eat, drink, socialise and spend.

This is where it becomes a business story - and more importantly, a leadership one.

---

A shift hiding in plain sight

The UK has one of the highest obesity rates in Europe. According to the NHS, over a quarter of adults are classified as obese, with a further large proportion overweight. That alone explains why demand for GLP-1 medications has accelerated so quickly, but the impact is no longer confined to healthcare.

Emerging data points are starting to connect:

• The Office for National Statistics continues to track changes in household consumption patterns, including a gradual shift toward lower calorie and reduced portion food purchasing in certain demographics
• UK hospitality operators are reporting softening demand in high-margin categories such as desserts and alcohol in certain segments
• Global consumer businesses are beginning to signal that appetite-suppressing drugs could reshape long-term demand curves, not just short-term behaviour

Individually, these signals look incremental and taken together, they point to something more structural:

A cohort of consumers is changing its behaviour faster than the businesses serving it.

---

Why this is different from previous “health trends”

We have seen waves before: low fat, low carb, plant-based and most were gradual - in fact many were reversible. I don't think this is.

GLP-1 medications work by altering appetite regulation, so people eat less, and then they feel full sooner. In many cases, they lose interest in categories they previously consumed regularly.

That has second-order effects:

• Reduced food volume consumption
• Lower alcohol intake
• Changes in social habits centred around eating
• Increased focus on long-term health and personal optimisation

This is not preference, it is physiology and that makes it more durable.

---

The leadership challenge is not the drug, it is the speed.

The real issue for businesses is not whether this trend continues, it is whether leadership teams are equipped to respond to behavioural change at this pace.

Most organisations are structured to:

• Analyse trends retrospectively
• Validate them through multiple reporting cycles
• Respond incrementally

That model works when change is linear, but it fails when change is non-linear and human-led because by the time the data is conclusive, the behaviour is already embedded.

---

Where this becomes commercial

If even a modest percentage of the UK population adopts GLP-1 medications over the next five years, the implications are significant:

• Food and beverage: Portion sizes, menu design, pricing models
• Retail and FMCG: Demand forecasting, product mix, category growth assumptions
• Leisure and hospitality: Experience-led offerings replacing consumption-led revenue
• Healthcare and insurance: Long-term cost modelling and prevention strategies

This is not about decline, it is about redistribution of demand.

Some businesses will adapt early and capture it whereas others will continue optimising for a consumer that is already changing.

---

What this exposes about leadership

Many leadership teams are still:

• Hiring based on sector experience rooted in past models
• Rewarding operational efficiency over adaptive thinking
• Assuming that behavioural change will follow familiar patterns

But this environment demands something different:

• Leaders who can interpret weak signals early
• The judgement to act before full certainty
• The confidence to challenge deeply held assumptions about customers

Because the uncomfortable truth is this:

Markets do not wait for leadership teams to feel ready. They move, and advantage shifts to those who act first.

---

A sharper reality

This is not really about weight-loss drugs, it is about what happens when human behaviour shifts quickly and at scale, and whether leadership is capable of keeping pace.

Most organisations will not miss this because they failed to see it, they will miss it because they saw it too late to respond.

---

Where this becomes a leadership decision

At Friisberg UK, we are increasingly asked the same question in different forms:

What kind of leadership do we need for a market that is changing faster than our organisation is built to handle?

The answer is rarely found in a job description. It comes from experience, from pattern recognition across markets, from having seen cycles of change before and knowing when this time is different.

Friisberg is a long-established firm with deep, cross-sector expertise and a genuinely international perspective. That matters at a point like this, because when behaviour shifts quickly, decisions cannot be made in isolation or based purely on precedent.

They require:

• Clear definition before the market forces it
• Alignment before ambiguity takes hold
• Leaders who are not just credible, but relevant to what comes next

This is the shift that matters:

When behaviour changes faster than businesses, leadership becomes the only real lever of advantage.

And the organisations that recognise that early do not just keep up, they move first.